Paul Tudor Jones Nuvalent, Inc. Transaction History
Tudor Investment Corp Et Al
- $25.1 Billion
- Q4 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Nuvalent, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 46,263 shares of NUVL stock, worth $3.59 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
46,263Holding current value
$3.59 Million% of portfolio
0.01%Shares
7 transactions
Others Institutions Holding NUVL
# of Institutions
232Shares Held
59MCall Options Held
834KPut Options Held
490K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.4 Billion34.87% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.36MShares$416 Million16.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.5MShares$349 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$235 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.62MShares$203 Million6.84% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.34B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...